Exec Chat: KCI CEO Andrew Eckert Foresees Big Year For Wound-Care Company
Executive Summary
Since selling its LifeCell aesthetic and surgical products business to Allergan in early 2017, Acelity has refocused its commercial efforts, and its name, on the KCI wound-care business, with significant investments in medical education, clinical studies and R&D in that sector, as well as the recent acquisition of UK-based Crawford Healthcare.
You may also be interested in...
Acelity Buys Crawford To Create Wound-Care Powerhouse
Acelity has agreed to acquire Crawford Healthcare for an undisclosed price to expand its wound care portfolio. Crawford's wound-dressing portfolio includes the KerraMax Care, KerraFoam, and KerraCel brands, complementing Acelity's advanced wound dressing line-up, which includes the Promogran Prisma Matrix collagen dressing, the Tielle dressings, and Adaptic dressings. The deal also includes Crawford's research and development and manufacturing facilities in Chesire, UK.
Kinetic Concepts continues wound care diversification with Systagenix buy
In a bid to counter increasing pressure on its core negative pressure wound care business, Kinetic Concepts is expanding its portfolio by agreeing to buy UK firm Systagenix for $485m. The deal, which is expected to close in the fourth quarter, is a “major step…towards increased revenue diversification and geographic expansion,” Kinetic said.
News We’re Watching: FDA Approves Medtronic's Affera, Roche's CGM Moves Closer To Approval, And More
Medtech Insight's News We're Watching covers medtech industry and research news you may have missed. This week, the Advanced Technologies and Treatments for Diabetes (ATTD) conference in Florence, Italy, included new results from studies of Roche's continuous glucose monitor and Medtronic's 780G insulin pump, Medtronic moved closer to earning FDA approval for its Affera ablation mapping and ablation system, and Linus Health expanded its technology for finding signs of cognitive problems in speech data.